Product Information
GRALISE ER 300 MG TABLET is a brand product labeled by Almatica Pharma LLC, priced at $10.1851 per EA under NDC 52427080390. Its NADAC has been published 286 times since Apr 14, 2021.
FDA first approved this application on Jan 28, 2011. Its Orange Book therapeutic-equivalence code is AB2 — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The High Outlier badge above means this manufacturer's average price in the gabapentin market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
300 mg/1
Manufacturer
Almatica Pharma LLCNDC
52427080390
Classification
Brand
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
GABAPENTINApproval Type
New Drug (NDA)
FDA Application
NDA022544FDA Approved
1/28/2011
TE Code
AB2
On Market Since
10/1/2020
Pharmacological Classes
Price Statistics
The NADAC for GRALISE ER 300 MG TABLET has been published 286 times since Apr 14, 2021, and over the history we have for it it has risen 14.5%. The table below summarizes its recorded NADAC range and movement.
| Current price | $10.1851 per EA |
|---|---|
| All-time high | $10.2379 (May 14, 2025) |
| All-time low | $8.8955 (Apr 14, 2021) |
| 52-week high | $10.2265 |
| 52-week low | $10.1783 |
| Median price | $10.1925 |
| Average price | $9.9292 |
| Largest weekly change | +6.0% (May 4, 2022) |
| Weeks tracked | 286 |
| Tracking since | Apr 14, 2021 |
Generic Alternatives
The matcher finds 2 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 94% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Almatica Pharma LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
gabapentin market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of GRALISE ER 300 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for GRALISE ER 300 MG TABLET, manufactured by Almatica Pharma LLC, is $10.1851 per EA (NDC 52427080390), effective Sep 30, 2026.
How has the price of GRALISE ER 300 MG TABLET changed over time?
Over the history we have for it, the NADAC for GRALISE ER 300 MG TABLET has risen 14.5%. It has been tracked across 286 weekly CMS publications since Apr 14, 2021.
What are the highest and lowest recorded NADAC prices for GRALISE ER 300 MG TABLET?
Since Apr 14, 2021, the NADAC for GRALISE ER 300 MG TABLET has ranged from a low of $8.8955 (Apr 14, 2021) to a high of $10.2379 (May 14, 2025), with a median of $10.1925 per EA.
Are there cheaper alternatives to GRALISE ER 300 MG TABLET?
Yes. 2 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, GABAPENTIN ER 300 MG TABLET, is $0.6385 per EA — about 94% below GRALISE ER 300 MG TABLET.
Who manufactures GRALISE ER 300 MG TABLET?
GRALISE ER 300 MG TABLET (NDC 52427080390) is labeled by Almatica Pharma LLC, and CMS classifies it as a brand product.